Replicate Bioscience
Self-replicating RNA (srRNA) therapeutics and vaccines
Biotech
📍 San Diego, CA
Founded 2020
Current Valuation
Private
PRIVATE
Replicate Bioscience is a San Diego biotech founded in 2020 by RNA-vaccine veterans Nathaniel Wang (CEO) and Andrew Geall to build self-replicating RNA (srRNA) medicines designed to be more durable, tolerable and lower-dose than conventional mRNA. It raised a $40M Series A from Apple Tree Partners in 2021 and has partnered with Novo Nordisk to develop srRNA therapies for obesity and diabetes.
Company Profile
Growth
Clinical-stage srRNA platform; advancing partnered programs
Last Round
Series A — $40M (Jan 2021) · Lead: Apple Tree Partners
Fundraising Status
Series A · $40M · 5y 6mo ago
privateTotal raised $40M1 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Series A | $40M | Jan 2021 | Apple Tree Partners | — |
Founders & Key People
Nathaniel WangAndrew Geall
Investors
Apple Tree Partners (ATP)
Products
- Self-replicating RNA (srRNA) platform
- srRNA vaccines and therapeutics
Competitors
Arcturus Therapeutics · Gritstone bio · Therna Biosciences
BiotechRNA TherapeuticsSelf-amplifying RNATechBio
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.